Core Scientific is being taken private by CoreWeave. The merger agreement, filed July 7, 2025, converts every share of $CORZ common stock into 0.1235 shares of CoreWeave Class A common stock. That exchange ratio is the number that matters most to current shareholders, because it fixes the consideration and removes any cash alternative.
The structure is a standard forward triangular merger. Miami Merger Sub I, a CoreWeave wholly owned subsidiary, merges into Core Scientific, with Core Scientific surviving as a wholly owned subsidiary of CoreWeave. $CORZ shareholders end up holding CoreWeave Class A shares, not cash, which means their outcome is tied to CoreWeave's equity value at closing.
The Termination Fee Sets the Floor on Board Commitment
The board of directors of Core Scientific is required to recommend the transaction. That obligation has teeth. If the board changes its recommendation and CoreWeave elects to terminate, Core Scientific owes CoreWeave a $270 million termination fee. The filing also preserves a standard fiduciary out: the board can change its recommendation in response to a superior proposal, but the fee applies if CoreWeave then walks. That $270 million figure is the market's clearest signal of how seriously both sides priced board commitment into the deal structure.
The outside date for closing is April 7, 2026. Either party can terminate if the merger has not closed by then, subject to the standard cure and breach provisions. Regulatory approvals are required, and both parties have committed to reasonable best efforts to obtain them, including under antitrust law.
Officer Departures Are Built Into the Deal
Item 5.02 of the 8-K discloses letter agreements with certain officers. Each agreement provides that the officer will separate from Core Scientific on the closing date, with that separation treated as a resignation for good reason. Outstanding RSU and PSU awards vest at the effective time and convert into the right to receive the merger consideration on the same per-share basis as common stockholders. The letter agreements also include excise tax reimbursement provisions tied to the merger, which are automatically revoked if the merger agreement terminates without closing.
The officer departure structure is not unusual for a deal of this type, but the explicit RSU and PSU acceleration language in the 8-K is worth reading carefully. It means equity-compensated officers are economically aligned with closing, not with any alternative transaction.
CORZ's Filing Risk Signal Reflects the Event
$CORZ's Filing Risk Score sits at 100, the ceiling, driven by the density and severity of recent filings. A signed merger agreement is exactly the kind of material event that pushes that signal to its highest level. The Event Momentum score is also at 100, reflecting the weight of this filing relative to Core Scientific's recent disclosure history. These are disclosure-intensity readings, not judgments about deal quality or company health.
$CORZ's BTC Exposure Score is 80, placing Bitcoin firmly at the center of the company's research case through its mining and hosting operations. That exposure does not transfer to CoreWeave shareholders in the same form. CoreWeave is an AI infrastructure company, and the combined entity's Bitcoin sensitivity will depend entirely on how CoreWeave accounts for and operates any retained mining assets after closing.
What the Exchange Ratio Means in Practice
$CORZ had been trading in an uptrend through mid-May 2026, up roughly 17% over the prior month and more than 45% year to date as of the most recent cached price context. The stock hit a 52-week high of $25.17 on May 14, 2026, six days before the cached snapshot date. The merger consideration is fixed at 0.1235 CoreWeave Class A shares per $CORZ share, so the realized value for $CORZ shareholders depends on where CoreWeave trades at closing, not where $CORZ trades today.
That dynamic is the central risk for current $CORZ holders who stay through closing. The exchange ratio does not float. If CoreWeave's stock declines between signing and closing, the per-share value of the consideration declines with it. The merger agreement does not include a price-based walk right for Core Scientific.
The proxy statement and prospectus, which will be filed as part of a Form S-4 registration statement, will contain the full fairness analysis, financial projections, and board deliberation record. Those documents are the next material read for anyone evaluating whether the exchange ratio reflects fair value for $CORZ shareholders.
Research only. Not investment advice.